Asymmetric dimethylarginine (ADMA): Is really a biomarker for cardiovascular prognosis?

被引：10
|
作者：
Tousoulis, Dimitris [1 ]
Siasos, Gerasimos [1 ,2 ]
Oikonomou, Evangelos [1 ]
Stougianos, Pavlos [2 ]
Papageorgiou, Nikolaos [1 ]
机构：
[1] Univ Athens, Sch Med, Hippokrat Hosp, Cardiol Dept 1, GR-11527 Athens, Greece
[2] Univ Athens, Sch Med, Dept Biol Chem, GR-11527 Athens, Greece
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2011年 / 153卷 / 02期
关键词：
Asymmetric dimethylarginine; Biomarker; Cardiovascular disease; Atherosclerosis; CORONARY-ARTERY-DISEASE; STAGE RENAL-DISEASE; L-ARGININE; PLASMA-LEVELS; RISK; EVENTS; MORTALITY; MARKER; DEATH;
D O I：
10.1016/j.ijcard.2011.08.070
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：123 / 125
页数：3
相关论文
共 50 条
  • [31] Asymmetric dimethylarginine (ADMA) in EBC of asthmatic children
    Carraro, Silvia
    Di Gangi, Iole Maria
    Piacentini, Giorgio
    Kantar, Ahmad
    Moser, Serena
    Cesca, Laura
    Berardi, Mariangela
    Giordano, Giuseppe
    Baraldi, Eugenio
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [32] Asymmetric dimethylarginine (ADMA) and acute vascular events
    Valkonen, VP
    Laaksonen, R
    CLINICA CHIMICA ACTA, 2004, 348 (1-2) : 9 - 17
  • [33] Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis
    Cooke, JP
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (Suppl 1) : 115 - 121
  • [34] Effects of asymmetric dimethylarginine (ADMA) infusion in humans
    Jan T. Kielstein
    Dimitrios Tsikas
    Danilo Fliser
    European Journal of Clinical Pharmacology, 2006, 62 : 39 - 44
  • [35] Effects of asymmetric dimethylarginine (ADMA) infusion in humans
    Kielstein, JT
    Tsikas, D
    Fliser, D
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (Suppl 1) : 39 - 44
  • [36] Asymmetric Dimethylarginine (ADMA) in Pediatric Renal Diseases: From Pathophysiological Phenomenon to Clinical Biomarker and Beyond
    Hsu, Chien-Ning
    Tain, You-Lin
    CHILDREN-BASEL, 2021, 8 (10):
  • [37] Cardiovascular effects of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and evidence for ADMA metabolism in humans in vivo
    Achan, V
    Broadhead, M
    Malaki, M
    Leiper, J
    MacAllister, R
    Vallance, P
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 303A - 303A
  • [38] Evaluation of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in patient with erectile dysfunction
    Barassi, A.
    Paroni, R.
    Fermo, I.
    Biondi, M. L.
    Pavlovic, R.
    Piediferro, G.
    Colpi, G. M.
    d'Eril, G. V. Melzi
    CLINICAL CHEMISTRY, 2007, 53 (06) : A171 - A171
  • [39] Human hemoglobin does not contain asymmetric dimethylarginine (ADMA)
    Boehmer, Anke
    Grosskopf, Henning
    Jordan, Jens
    Tsikas, Dimitrios
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2012, 27 (01): : 72 - 74
  • [40] Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule
    Colonna, Vito De Gennaro
    Bianchi, Mauro
    Pascale, Valerio
    Ferrario, Paolo
    Morelli, Franca
    Pascale, Walter
    Tomasoni, Livio
    Turiel, Maurizio
    MEDICAL SCIENCE MONITOR, 2009, 15 (04): : RA91 - RA101
12345